Quest Diagnostics updates 2023-2026 outlook: mid single-digit revenue CAGR, high single-digit adjusted EPS CAGR

QUEST DIAGNOSTICS INC

Reiterates 2023 guidance: revenue $8.83B-$9.03B, base business +2.6%-3.8%, adjusted EPS $8.40-$9.00.
Long-term 2023-2026: mid single-digit revenue CAGR; high single-digit adjusted EPS CAGR.
Invigorate program targets ~3% annual productivity savings via automation, AI, and digital.
Growth initiatives: physician/hospital expansion, molecular genomics, oncology, consumer health.
No change to 2023 guidance; capital deployment strategy discussed without new commitments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.